Failure to Diagnose Skin Cancer and Melanoma Lawyer New York

How Skin Cancer and Melanoma Are Diagnosed

Skin cancer diagnosis involves visual examination, dermoscopy, biopsy, and pathology:

• Skin examination: A dermatologist or other physician examines the skin for suspicious lesions -- looking for the ABCDE signs of melanoma (Asymmetry, Border irregularity, Color variation, Diameter greater than 6mm, Evolving or changing).
• Dermoscopy (epiluminescence microscopy): A handheld magnifying instrument that allows the dermatologist to examine the subsurface structures of a skin lesion. Dermoscopy significantly improves the accuracy of melanoma diagnosis compared to naked-eye examination.
• Biopsy: The standard for definitive diagnosis. A dermatologist or surgeon removes all or part of the suspicious lesion for pathological examination. Types of biopsy include: shave biopsy (removing the top layer), punch biopsy (removing a small cylinder of tissue), excisional biopsy (removing the entire lesion), and incisional biopsy (removing part of a large lesion).
• Pathology (dermatopathology): Tissue samples are examined by a pathologist or dermatopathologist (a specialist in skin pathology) under a microscope. The pathologist determines whether cancer is present, the type (melanoma, basal cell carcinoma, squamous cell carcinoma), and for melanoma, the Breslow depth (how deeply the melanoma has invaded the skin), which is the most important prognostic factor.
• Sentinel lymph node biopsy: For melanomas that meet certain criteria (typically Breslow depth greater than 0.8mm), a sentinel lymph node biopsy may be performed to determine whether the cancer has spread to nearby lymph nodes.
• Imaging for staging: CT, PET, or MRI to determine whether melanoma has spread to distant organs.

Types of Skin Cancer

There are three main types of skin cancer, each with different characteristics and prognoses:

• Melanoma: The deadliest form of skin cancer, arising from melanocytes (pigment-producing cells). Melanoma can occur anywhere on the skin, including areas not exposed to the sun. It is highly aggressive and can spread rapidly to lymph nodes and distant organs. The Breslow depth (how deeply the melanoma has invaded) is the most important prognostic factor.
• Basal cell carcinoma (BCC): The most common form of skin cancer, arising from basal cells in the epidermis. BCC is usually slow-growing and rarely metastasizes, but can cause significant local tissue destruction if not treated. BCC typically occurs on sun-exposed areas (face, ears, neck, scalp, shoulders).
• Squamous cell carcinoma (SCC): The second most common form of skin cancer, arising from squamous cells in the epidermis. SCC is more aggressive than BCC and can metastasize, particularly when it occurs on the lips, ears, or in immunosuppressed patients. SCC typically occurs on sun-exposed areas.
• Other types: Less common types include Merkel cell carcinoma (a rare, aggressive neuroendocrine tumor of the skin), dermatofibrosarcoma protuberans, and cutaneous lymphoma.

Common Ways Skin Cancer Is Misdiagnosed

Skin cancer misdiagnosis can occur at any point in the diagnostic process:

• Failure to perform a skin examination: A physician does not examine the skin during a routine visit, missing a suspicious lesion. The standard of care for a full skin examination varies depending on the setting and patient risk factors, but patients with risk factors (fair skin, history of sunburn, family history, numerous moles, immunosuppression) should have regular skin examinations.
• Failure to recognize a suspicious lesion: A physician examines the skin but does not recognize that a lesion has concerning features (the ABCDE signs of melanoma, or the characteristics of BCC or SCC).
• Misdiagnosis of a suspicious lesion as benign: A physician diagnoses a suspicious lesion as a benign condition (seborrheic keratosis, mole, wart, cyst) without biopsy. This is one of the most common errors in skin cancer diagnosis.
• Failure to biopsy a suspicious lesion: When a lesion has concerning features, the standard of care requires a biopsy. Failure to biopsy may allow cancer to go undetected and progress.
• Inadequate biopsy: The biopsy technique is inappropriate for the lesion. For example, a shave biopsy of a suspected melanoma can make it difficult to determine the Breslow depth (because the deep margin may be cut through), which is critical for staging and treatment. An excisional biopsy is preferred for suspected melanoma.
• Pathology errors: The pathologist or dermatopathologist misinterprets the biopsy tissue -- diagnosing cancer when it is not present (false positive), missing cancer that is present (false negative), or misclassifying the type or depth of invasion. Under-staging a melanoma (calling it a lower Breslow depth than it actually is) can lead to undertreatment, including failure to perform sentinel lymph node biopsy.
• Failure to communicate or follow up: Abnormal biopsy results are not communicated to the patient, or follow-up appointments are not arranged. [Link to: /radiology-errors/communication-failures]
• Failure to refer to a dermatologist: A primary care physician evaluates a suspicious lesion but does not refer the patient to a dermatologist for further evaluation and biopsy.

The ABCDE Rule for Melanoma

The ABCDE rule is a guideline for identifying melanoma. Physicians and patients should look for these signs when examining moles and skin lesions:

- A -- Asymmetry: One half of the mole does not match the other half. - B -- Border irregularity: The edges are ragged, notched, or blurred. - C -- Color variation: The color is not uniform, with shades of tan, brown, black, and sometimes red, white, or blue. - D -- Diameter: The mole is larger than 6 millimeters (about the size of a pencil eraser), although melanomas can sometimes be smaller. - E -- Evolving: The mole is changing in size, shape, color, or elevation, or is new or different from other moles.

Any lesion that meets one or more of the ABCDE criteria should be evaluated by a dermatologist and considered for biopsy. Failure to recognize and biopsy a lesion with ABCDE features may constitute negligence.

In addition to the ABCDE rule, the ugly duckling sign is another important guideline: a mole that looks different from the patient other moles (the ugly duckling) should be considered suspicious, even if it does not meet the ABCDE criteria.

Biopsy Errors in Skin Cancer

Biopsy technique is critical in skin cancer diagnosis, and errors can have serious consequences:

- Inadequate biopsy technique: The biopsy does not remove enough tissue for diagnosis, or the tissue is damaged during removal, making it difficult for the pathologist to interpret. - Shave biopsy of suspected melanoma: A shave biopsy (removing only the top layer of the lesion) is generally not recommended for suspected melanoma because it may not provide the full depth of the lesion, making it impossible to determine the Breslow depth accurately. An excisional biopsy (removing the entire lesion with a margin of normal skin) is preferred. - Incomplete excisional biopsy: The biopsy does not remove the entire lesion, leaving behind cancerous tissue and making it difficult to assess the margins. - Punch biopsy of a large lesion: A punch biopsy (removing a small cylinder of tissue) may be appropriate for a large lesion, but multiple biopsies from different areas may be needed to ensure representative sampling. - Failure to biopsy the most suspicious area: For a large lesion with varying characteristics, the biopsy should be taken from the most suspicious area. Biopsying a less suspicious area may miss the cancer. - Improper handling of the specimen: The tissue specimen must be properly handled, labeled, and transported to the pathology lab. Errors in handling can compromise the diagnosis.

Pathology Errors in Skin Cancer

Pathology errors are a significant cause of skin cancer misdiagnosis:

- False negative: The pathologist misses cancer that is present in the biopsy tissue. The patient is told the lesion is benign, and the cancer goes untreated. - False positive: The pathologist diagnoses cancer when it is not present, leading to unnecessary surgery and treatment. - Misclassification: The pathologist misclassifies the type of skin cancer (e.g., calling a melanoma a squamous cell carcinoma), leading to inappropriate treatment. - Under-staging of melanoma: The pathologist underestimates the Breslow depth (how deeply the melanoma has invaded), leading to undertreatment. The Breslow depth determines staging and treatment -- deeper melanomas require wider excision and may require sentinel lymph node biopsy. - Failure to assess margins: The pathologist must assess whether the cancer has been completely removed (clear margins) or whether cancer cells extend to the edge of the biopsy (positive margins). Positive margins require additional surgery. - Failure to test for molecular markers: For advanced melanoma, testing for certain genetic markers (BRAF mutation) guides treatment decisions. Failure to test may deny the patient access to targeted therapies.

An independent dermatopathologist should review the slides in any case of suspected pathology error. [Link to: /medical-malpractice/pathology-errors]

When Skin Cancer Misdiagnosis Constitutes Malpractice

Skin cancer misdiagnosis constitutes medical malpractice when a healthcare provider deviated from the accepted standard of care and that deviation caused harm. This includes:

• Failure to perform a skin examination: A physician did not examine the skin during a visit, particularly for a patient with risk factors.
• Failure to recognize a suspicious lesion: A physician examined the skin but did not recognize concerning features (ABCDE signs).
• Misdiagnosis of a suspicious lesion as benign: A suspicious lesion was diagnosed as a benign condition (seborrheic keratosis, mole, wart) without biopsy.
• Failure to biopsy a suspicious lesion: A lesion with concerning features was not biopsied.
• Inadequate biopsy technique: An inappropriate biopsy technique was used (e.g., shave biopsy of suspected melanoma), compromising the diagnosis.
• Pathology errors: The pathologist missed cancer, misclassified the type, or under-staged the melanoma.
• Failure to communicate or follow up: Abnormal results were not communicated, or follow-up was not arranged.
• Failure to refer to a dermatologist: A primary care physician did not refer a patient with a suspicious lesion to a dermatologist.

The Impact of Delayed Melanoma Diagnosis

The impact of a delayed melanoma diagnosis can be devastating:

- Breslow depth progression: The Breslow depth (how deeply the melanoma has invaded) is the most important prognostic factor. A delay in diagnosis allows the melanoma to invade more deeply, dramatically reducing survival. A melanoma that is less than 1mm deep has a 5-year survival of over 99%, while a melanoma deeper than 4mm has a 5-year survival of about 30%. - Stage progression: A melanoma that could have been diagnosed at stage 1 (5-year survival: 99%) may progress to stage 3 or 4 (5-year survival: 35% for distant metastasis) due to delayed diagnosis. - Spread to lymph nodes and distant organs: Melanoma can spread to lymph nodes, lungs, liver, brain, and other organs. Metastatic melanoma is much harder to treat. - More aggressive treatment: Later-stage melanoma requires more aggressive treatment -- wider excision, lymph node dissection, immunotherapy, targeted therapy, and chemotherapy. - Reduced survival: The most devastating consequence. A patient who could have been cured may face a terminal diagnosis. - Loss of chance: Even if the patient is not yet terminal, the delayed diagnosis may have reduced their chance of survival. [Link to: /delayed-diagnosis-lawyer/loss-of-chance]

Lavern's Law and Your Deadline to File

Skin cancer and melanoma misdiagnosis cases in New York are subject to Lavern's Law, which provides a discovery rule for cancer cases. Under Lavern's Law:

- You have 2.5 years from the date you discovered (or should have discovered) the misdiagnosis to file a lawsuit. - There is an absolute outer limit of 7 years from the date of the negligent act.

This means that even if years have passed since the misdiagnosis, you may still have a valid claim if you discovered the error recently. For example, if you were diagnosed with advanced melanoma in 2024 and discovered in 2025 that a dermatologist misdiagnosed a suspicious mole as benign in 2020, you would have 2.5 years from the date of discovery to file.

Lavern's Law applies only to cancer cases. [Link to: /misdiagnosis/laverns-law]

If the misdiagnosis resulted in death, a wrongful death claim under EPTL 5-4.1 must be filed within 2 years of the date of death. [Link to: /wrongful-death-lawyer]

Common Defense Arguments and How We Counter Them

Defense: The lesion did not have concerning features at the time of examination.

Defense attorneys use several arguments in skin cancer misdiagnosis cases:

• Our Counter: We use expert testimony from dermatologists to establish that the lesion had concerning features (ABCDE signs or the ugly duckling sign) that a competent dermatologist would have recognized. We also examine clinical photographs (if available) and the subsequent appearance of the lesion. If the lesion was documented as having concerning features but was not biopsied, it may constitute negligence.

Defense: The lesion was difficult to diagnose, and reasonable physicians could disagree.

Our Counter: While some skin lesions are genuinely difficult to diagnose, the standard of care requires biopsy when there is clinical suspicion. If the lesion had any concerning features, the standard of care required biopsy. Failure to biopsy a suspicious lesion -- even one that is difficult to diagnose -- may constitute negligence.

Defense: The biopsy was performed correctly, but the pathology was ambiguous.

Our Counter: If the pathology was ambiguous, the standard of care may require consultation with a dermatopathologist (a specialist in skin pathology) or repeat biopsy. We have the slides independently reviewed by a qualified dermatopathologist.

Defense: The delayed diagnosis did not change the outcome.

Our Counter: We use oncologist expert testimony to establish that earlier diagnosis would have changed the outcome -- that the melanoma was at a treatable stage when it should have been diagnosed, and that the delay allowed it to progress. The Breslow depth at the time of actual diagnosis (compared to the expected depth at the time of the negligent examination) is key evidence. The loss of chance doctrine may also apply. [Link to: /delayed-diagnosis-lawyer/loss-of-chance]

Compensation Available in Skin Cancer Misdiagnosis Cases

A successful skin cancer misdiagnosis claim in New York can provide compensation for:

• Medical expenses: Additional surgery (wide excision, lymph node dissection), immunotherapy, targeted therapy, chemotherapy, radiation, reconstruction, ongoing care
• Lost wages and loss of earning capacity
• Pain and suffering: Physical pain, emotional distress, scarring, disfigurement, and loss of enjoyment of life (NY has no cap on non-economic damages)
• Permanent disability and disfigurement: From wide excision scars, lymphedema (from lymph node dissection), and metastatic disease
• Loss of chance of survival: The reduced chance of survival caused by the delayed diagnosis
• Wrongful death damages: If the delayed diagnosis caused death [Link to: /wrongful-death-lawyer]

What to Expect Working with MDLaw Firm

When you contact MDLaw Firm about a potential skin cancer misdiagnosis case:

• Free Consultation: We listen to your story and review the basic facts.
• Immediate Deadline Assessment: We evaluate the Lavern's Law deadline (2.5 years from discovery, 7-year outer limit).
• Record Retrieval: We obtain all dermatology records, biopsy results, pathology slides, clinical photographs, and medical records.
• Expert Dermatology Review: We engage board-certified dermatologists to evaluate whether the standard of care was met.
• Expert Pathology Review: We engage independent dermatopathologists to review the biopsy slides.
• Causation Analysis: We use oncologist expert testimony to establish that the delayed diagnosis caused the cancer to progress and reduced survival.
• Litigation: We file within Lavern's Law deadlines and handle all aspects of discovery and trial.
• Resolution: We pursue maximum compensation through settlement or verdict.

Frequently Asked Questions

The value of a medical malpractice case in New York depends on several factors, including the severity of the injury, the strength of liability evidence, and the economic and non-economic damages involved. New York is one of the few states with no caps on medical malpractice damages, meaning there is no artificial limit on what you can recover. Below are typical settlement ranges based on injury severity.